GLP-1 tachyphylaxis

Tachyphylaxis is the pharmacological term for a drug effect that fades with repeated exposure — not because the dose changed, but because the body adapted to it. In this category it describes something people notice within weeks: the drug’s grip on your stomach loosens even while it keeps working on appetite.

The clearest documentation is in the Zepbound label, which states that tirzepatide delays gastric emptying and that the delay is largest after the first dose and diminishes over time. That single sentence explains a great deal of lived experience: why nausea is worst at the start and after each increase, why early fullness eases after a month, and why a dose that felt overwhelming in week one feels manageable by week six.

The concept has direct clinical consequences beyond comfort. A 2024 review in the British Journal of Anaesthesia examined GLP-1 receptor agonist tachyphylaxis specifically in the context of perioperative recommendations — because if the gastric-emptying delay attenuates with duration, then how long someone has been on the drug may matter as much as when they last dosed when planning for anesthesia.

The confusion worth correcting is reading tachyphylaxis as “the drug stopped working.” Attenuation of the gastric-emptying effect is not the same as loss of weight-loss effect. Trials show continued weight reduction well past the point where early nausea has settled, and in SURMOUNT-4 people who stayed on tirzepatide after a 36-week lead-in lost a further 5.5% over the following year. A genuine plateau has different causes.

This is worth raising if side effects vanished and you concluded the medication had quit. Ask whether your appetite and intake have actually changed, whether there is room left on the dose ladder, and — before any procedure — how long you have been treated. Our dose wearing-off review and side-effect timeline go further.